A5112897059- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Biosimilars and Bioanalytical Methods
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Integrated Circuits and Semiconductor Failure Analysis
- Pluripotent Stem Cells Research
- Advancements in Semiconductor Devices and Circuit Design
Zhejiang University
2023-2025
First Affiliated Hospital Zhejiang University
2023-2024
Zhejiang Chinese Medical University
2023
Background Murine chimeric antigen receptor T (CAR-T) cell therapy has demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, the potential immunogenicity of murine single-chain variable fragment domain may limit persistence CAR-T cell, leading to relapse. Methods We performed a trial determine safety and efficacy autologous allogeneic humanized CD19-targeted (hCART19) for R/R B-ALL. Fifty-eight (aged 13–74 years) were...
B-cell maturation antigen (BCMA)-targeting chimeric receptor (CAR) T-cell immunotherapy has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). This study presents updated long-term outcomes from our center. Between July 30, 2018, and September 27, 2023, 141 patients with R/RMM who received BCMA CAR-T therapy were enrolled. Patients underwent conditioning chemotherapy cyclophosphamide fludarabine, followed by cell infusion at a median dose 2.36×106...
Abstract Background Lysine [K] methyltransferase 2A ( KMT2A , previously known as MLL ) gene rearrangements are common in acute leukemias of various lineages and associated with features such chemotherapy resistance rapid relapse. KMT2A::CBL is a rare fusion unknown pathogenesis generated by unique interstitial deletion chromosome 11 that has been reported across wide age range both myeloid leukemia (AML) lymphoblastic (ALL) patients. The leukemogenic effect the rearrangement its association...